Indication

For the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy, alone or in combination with methotrexate (MTX).

Medicine details

Medicine name:
guselkumab (Tremfya)
SMC ID:
SMC2360
Pharmaceutical company
Janssen-Cilag Ltd
BNF chapter
Musculoskeletal and joint diseases
Submission type
Full
Publication due date:
09 August 2021
SMC meeting date:
06 July 2021
Patient group submission deadline:
31 May 2021